The European Hematology Association (EHA) Annual Congress is one of the most significant events in the field of hematology, bringing together experts, researchers and industry leaders from around the world.
The 3rd edition of the conference took place in Madrid, on 13-16 June 2024, to provide a closer look at the latest advancements in hematology, particularly around research, treatments and policy. This year’s theme focused on fostering innovation and collaboration to improve patient outcomes, emphasizing the role of cutting-edge technologies in shaping the future of hematology.
As part of this prestigious event, partners of GenoMed4All and sister project SYNTHEMA participated in a dedicated session organized by ERN-EuroBloodNet, titled ‘Data driven research & Innovative therapies’. María del Mar Mañú Pereira, Head of Rare Anemia Disorders Laboratory at Vall d’Hebron Institute of Research (VHIR), and Raffaella Colombatti, Pediatric Hematologist and Associate Professor at University of Padova, presented the core objectives of both EU-funded initiatives, with a particular focus on the work carried out for the Sickle Cell Disease case study.
Other GenoMed4All representatives also attended EHA 2024 in Madrid to help disseminate the project’s mission and engage with the broader hematology community, including: Federico Álvarez from Universidad Politecnica de Madrid, Matteo Della Porta from Humanitas Research Hospital, and Diana López from AUSTRALO.
Being present at such a high-profile event is crucial for increasing awareness about our work, and contributing to discussions on the latest scientific and technological developments in the field. Beyond the scientific discourse, EHA 2024 reaffirmed the importance of collective efforts in driving innovation and improving patient care, reinforcing GenoMed4All’s commitment to advancing hematological research through technology-driven solutions.
